Massachusetts lost biomanufacturing jobs last year, raising questions about the sector’s future in the state. But local and state leaders are planning initiatives to show the Bay State remains a formidable powerhouse.
A joint venture including CBRE Investment Management has joined the ownership structure of a Kendall Square office-lab building anchored by Facebook parent Meta Platforms and Bristol Myers Squibb.
With an additional 113,000-square-foot commitment, Bristol Myers Squibb has spoken for all of the office-lab space in DivcoWest’s 250 Water St. development at Cambridge Crossing.
A surge of developments and business expansions – ranging from clean energy to biomanufacturing and life science research – at the state-run Devens business park are shattering the narrative of stagnant commercial real estate prospects outside Interstate 495.
A Cambridge-based energy company that’s collaborating with Massachusetts Institute of Technology on climate change-fighting technology will occupy a new 160,000-square-foot manufacturing facility developed by King Street Properties of Boston at Devens.
Bristol-Myers Squibb will consolidate a pair of Cambridge facilities at a new 504,000-square-foot office-lab building under construction at Cambridge Crossing, becoming the fourth major commercial tenant of the DivcoWest development.
Miway Corp. has sold a former Bristol-Myers Squibb manufacturing building at 35 South St. in Hopkinton to LakePharma Inc. for $4.55 million.
A zoning change approved by voters in three communities will create a 40-acre site available for commercial use in the north central Massachusetts enterprise zone Devens, a space that could serve as a future home for a pharmaceutical company or other life-sciences and technology-based businesses.
